CN113197991A - Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof - Google Patents
Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof Download PDFInfo
- Publication number
- CN113197991A CN113197991A CN202110619720.6A CN202110619720A CN113197991A CN 113197991 A CN113197991 A CN 113197991A CN 202110619720 A CN202110619720 A CN 202110619720A CN 113197991 A CN113197991 A CN 113197991A
- Authority
- CN
- China
- Prior art keywords
- parts
- traditional chinese
- chinese medicine
- medicine composition
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003814 drug Substances 0.000 title claims abstract description 101
- 239000000203 mixture Substances 0.000 title claims abstract description 41
- 201000010065 polycystic ovary syndrome Diseases 0.000 title claims abstract description 26
- 238000002360 preparation method Methods 0.000 title claims abstract description 23
- 206010036049 Polycystic ovaries Diseases 0.000 title abstract description 17
- 210000003734 kidney Anatomy 0.000 claims abstract description 30
- 206010062717 Increased upper airway secretion Diseases 0.000 claims abstract description 21
- 208000026435 phlegm Diseases 0.000 claims abstract description 21
- 230000007812 deficiency Effects 0.000 claims abstract description 19
- 238000001467 acupuncture Methods 0.000 claims abstract description 14
- 229940079593 drug Drugs 0.000 claims abstract description 12
- 210000000582 semen Anatomy 0.000 claims description 3
- 241000628997 Flos Species 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 15
- 239000008280 blood Substances 0.000 abstract description 12
- 210000004369 blood Anatomy 0.000 abstract description 12
- 240000009138 Curcuma zedoaria Species 0.000 abstract description 9
- 244000020518 Carthamus tinctorius Species 0.000 abstract description 8
- 235000003255 Carthamus tinctorius Nutrition 0.000 abstract description 8
- 241000304195 Salvia miltiorrhiza Species 0.000 abstract description 8
- 235000011135 Salvia miltiorrhiza Nutrition 0.000 abstract description 8
- 241001078983 Tetradium ruticarpum Species 0.000 abstract description 8
- 235000003405 Curcuma zedoaria Nutrition 0.000 abstract description 7
- 244000178320 Vaccaria pyramidata Species 0.000 abstract description 7
- 230000017531 blood circulation Effects 0.000 abstract description 7
- 235000017803 cinnamon Nutrition 0.000 abstract description 7
- 230000001737 promoting effect Effects 0.000 abstract description 7
- 235000010587 Vaccaria pyramidata Nutrition 0.000 abstract description 6
- 239000001812 curcuma zedoaria berg. rosc. Substances 0.000 abstract description 6
- 230000008961 swelling Effects 0.000 abstract description 6
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 6
- 235000019509 white turmeric Nutrition 0.000 abstract description 6
- 235000009051 Ambrosia paniculata var. peruviana Nutrition 0.000 abstract description 5
- 235000003097 Artemisia absinthium Nutrition 0.000 abstract description 5
- 240000001851 Artemisia dracunculus Species 0.000 abstract description 5
- 235000017731 Artemisia dracunculus ssp. dracunculus Nutrition 0.000 abstract description 5
- 235000003261 Artemisia vulgaris Nutrition 0.000 abstract description 5
- 241000893536 Epimedium Species 0.000 abstract description 5
- 240000009022 Smilax rotundifolia Species 0.000 abstract description 5
- 235000003205 Smilax rotundifolia Nutrition 0.000 abstract description 5
- 239000001138 artemisia absinthium Substances 0.000 abstract description 5
- 235000018905 epimedium Nutrition 0.000 abstract description 5
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 abstract description 5
- 241000173529 Aconitum napellus Species 0.000 abstract description 3
- 208000004880 Polyuria Diseases 0.000 abstract description 2
- 238000010521 absorption reaction Methods 0.000 abstract description 2
- 230000035619 diuresis Effects 0.000 abstract description 2
- 238000010792 warming Methods 0.000 abstract description 2
- 244000223760 Cinnamomum zeylanicum Species 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- 201000010099 disease Diseases 0.000 description 9
- 210000001672 ovary Anatomy 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- 239000000463 material Substances 0.000 description 8
- 230000005906 menstruation Effects 0.000 description 7
- 210000004291 uterus Anatomy 0.000 description 7
- 241000723347 Cinnamomum Species 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 239000005556 hormone Substances 0.000 description 6
- 229940088597 hormone Drugs 0.000 description 6
- 201000010066 hyperandrogenism Diseases 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 230000001850 reproductive effect Effects 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 201000000736 Amenorrhea Diseases 0.000 description 5
- 206010001928 Amenorrhoea Diseases 0.000 description 5
- 231100000540 amenorrhea Toxicity 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 208000002874 Acne Vulgaris Diseases 0.000 description 4
- 206010020112 Hirsutism Diseases 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 4
- 208000008589 Obesity Diseases 0.000 description 4
- 206010000496 acne Diseases 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000000509 infertility Diseases 0.000 description 4
- 230000036512 infertility Effects 0.000 description 4
- 231100000535 infertility Toxicity 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 235000020824 obesity Nutrition 0.000 description 4
- 230000027758 ovulation cycle Effects 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 210000000952 spleen Anatomy 0.000 description 4
- 241000227129 Aconitum Species 0.000 description 3
- 241001671653 Aconitum carmichaelii Species 0.000 description 3
- 108010005853 Anti-Mullerian Hormone Proteins 0.000 description 3
- 241000208838 Asteraceae Species 0.000 description 3
- 102000009151 Luteinizing Hormone Human genes 0.000 description 3
- 108010073521 Luteinizing Hormone Proteins 0.000 description 3
- 102100030173 Muellerian-inhibiting factor Human genes 0.000 description 3
- 244000272264 Saussurea lappa Species 0.000 description 3
- 235000006784 Saussurea lappa Nutrition 0.000 description 3
- 208000031975 Yang Deficiency Diseases 0.000 description 3
- 230000002159 abnormal effect Effects 0.000 description 3
- 239000000868 anti-mullerian hormone Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 229940040129 luteinizing hormone Drugs 0.000 description 3
- 230000016087 ovulation Effects 0.000 description 3
- 230000008506 pathogenesis Effects 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000002604 ultrasonography Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 206010000077 Abdominal mass Diseases 0.000 description 2
- 241000123844 Artemisia anomala Species 0.000 description 2
- 235000014290 Artemisia anomala Nutrition 0.000 description 2
- 241000481604 Bolbostemma Species 0.000 description 2
- 244000037364 Cinnamomum aromaticum Species 0.000 description 2
- 241000963421 Curcuma kwangsiensis Species 0.000 description 2
- 235000003397 Curcuma kwangsiensis Nutrition 0.000 description 2
- 241000963390 Curcuma wenyujin Species 0.000 description 2
- 235000003394 Curcuma wenyujin Nutrition 0.000 description 2
- 206010014733 Endometrial cancer Diseases 0.000 description 2
- 206010014759 Endometrial neoplasm Diseases 0.000 description 2
- 241001362421 Epimedium brevicornu Species 0.000 description 2
- 208000037093 Menstruation Disturbances Diseases 0.000 description 2
- 208000011707 Ovulation disease Diseases 0.000 description 2
- 241001072909 Salvia Species 0.000 description 2
- 235000017276 Salvia Nutrition 0.000 description 2
- 241001404789 Smilax glabra Species 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000001919 adrenal effect Effects 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 230000002175 menstrual effect Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 210000004681 ovum Anatomy 0.000 description 2
- 238000003825 pressing Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 1
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 201000005670 Anovulation Diseases 0.000 description 1
- 206010002659 Anovulatory cycle Diseases 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 241000133570 Berberidaceae Species 0.000 description 1
- 208000019838 Blood disease Diseases 0.000 description 1
- 241000481605 Bolbostemma paniculatum Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000219321 Caryophyllaceae Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000196240 Characeae Species 0.000 description 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 description 1
- 235000021511 Cinnamomum cassia Nutrition 0.000 description 1
- 206010010356 Congenital anomaly Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 241000219104 Cucurbitaceae Species 0.000 description 1
- 240000005629 Curcuma phaeocaulis Species 0.000 description 1
- 235000003391 Curcuma phaeocaulis Nutrition 0.000 description 1
- 208000014311 Cushing syndrome Diseases 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000893531 Epimedium koreanum Species 0.000 description 1
- 241001660849 Epimedium pubescens Species 0.000 description 1
- 241001362411 Epimedium sagittatum Species 0.000 description 1
- 241001362415 Epimedium wushanense Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 229930186217 Glycolipid Natural products 0.000 description 1
- 241001272567 Hominoidea Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021033 Hypomenorrhoea Diseases 0.000 description 1
- 241000207923 Lamiaceae Species 0.000 description 1
- 241000218195 Lauraceae Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 206010027339 Menstruation irregular Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 208000002500 Primary Ovarian Insufficiency Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 241000218201 Ranunculaceae Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 241001093501 Rutaceae Species 0.000 description 1
- 241000612118 Samolus valerandi Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 208000024799 Thyroid disease Diseases 0.000 description 1
- 235000004877 Vaccaria hispanica subsp hispanica Nutrition 0.000 description 1
- 240000001717 Vaccinium macrocarpon Species 0.000 description 1
- 235000012545 Vaccinium macrocarpon Nutrition 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 241000234299 Zingiberaceae Species 0.000 description 1
- 201000010272 acanthosis nigricans Diseases 0.000 description 1
- 229940023019 aconite Drugs 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 231100000552 anovulation Toxicity 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 230000002051 biphasic effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 235000004634 cranberry Nutrition 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 230000035558 fertility Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000008217 follicular development Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 239000010977 jade Substances 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 230000008376 long-term health Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000003821 menstrual periods Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229960000715 nimodipine Drugs 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001072 progestational effect Effects 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 208000021510 thyroid gland disease Diseases 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H39/00—Devices for locating or stimulating specific reflex points of the body for physical therapy, e.g. acupuncture
- A61H39/06—Devices for heating or cooling such points within cell-life limits
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/285—Aucklandia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/286—Carthamus (distaff thistle)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/29—Berberidaceae (Barberry family), e.g. barberry, cohosh or mayapple
- A61K36/296—Epimedium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/36—Caryophyllaceae (Pink family), e.g. babysbreath or soapwort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/537—Salvia (sage)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/714—Aconitum (monkshood)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
- A61K36/754—Evodia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/90—Smilacaceae (Catbrier family), e.g. greenbrier or sarsaparilla
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/02—Characteristics of apparatus not provided for in the preceding codes heated or cooled
- A61H2201/0207—Characteristics of apparatus not provided for in the preceding codes heated or cooled heated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61H—PHYSICAL THERAPY APPARATUS, e.g. DEVICES FOR LOCATING OR STIMULATING REFLEX POINTS IN THE BODY; ARTIFICIAL RESPIRATION; MASSAGE; BATHING DEVICES FOR SPECIAL THERAPEUTIC OR HYGIENIC PURPOSES OR SPECIFIC PARTS OF THE BODY
- A61H2201/00—Characteristics of apparatus not provided for in the preceding codes
- A61H2201/10—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy
- A61H2201/105—Characteristics of apparatus not provided for in the preceding codes with further special therapeutic means, e.g. electrotherapy, magneto therapy or radiation therapy, chromo therapy, infrared or ultraviolet therapy with means for delivering media, e.g. drugs or cosmetics
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Reproductive Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Rehabilitation Therapy (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating polycystic ovarian syndrome and a preparation method and application thereof. The invention provides a traditional Chinese medicine composition which comprises cinnamon, epimedium, monkshood, evodia rutaecarpa, glabrous greenbrier rhizome, rhizoma bolbostemmae, zedoary, diverse wormwood herb, safflower, salvia miltiorrhiza, cowherb seed and costustoot. The traditional Chinese medicine composition provided by the invention is subjected to medicine-separated moxibustion on the acupuncture points by the 12 traditional Chinese medicines, namely, the absorption of the effective components of the medicines by the skin tissues of the acupuncture points is promoted by means of the heat of moxibustion fire, so that the effects of warming yang and tonifying kidney, reducing phlegm and promoting diuresis, promoting blood circulation and removing blood stasis, and reducing swelling and dissipating stagnation are achieved, and the kidney deficiency and phlegm dampness type polycystic ovary syndrome and the kidney deficiency and phlegm stasis type polycystic ovary syndrome can be effectively treated.
Description
Technical Field
The invention relates to the field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating polycystic ovarian syndrome and a preparation method and application thereof.
Background
Polycystic ovary syndrome is a reproductive endocrine disorder disease which is mainly characterized by abnormal follicular development or anovulation and hyperandrogenism of women in the reproductive age and is accompanied with abnormal glycolipid metabolism. Hyperandrogenism and ovulation disorders are the main pathological features, and are clinically manifested as menstrual disorder (thin menstruation or even amenorrhea), infertility, hirsutism, acne, obesity, acanthosis nigricans, etc. Polycystic ovarian syndrome not only seriously affects the reproductive function of patients, but also easily causes endocrine hormone-related complications such as endometrial cancer, hypertension, diabetes and the like. Because the disease involves many factors such as hypothalamus, pituitary, ovary, adrenal gland and heredity, and presents high heterogeneity in pathogenesis, biochemical change and clinical manifestation, the disease not only increases the difficulty of diagnosis, but also becomes an intractable disease. The external changes (obesity, acne, hirsutism and the like) and the reproductive changes (menstruation, amenorrhea, infertility and the like) caused by the traditional Chinese medicine composition affect the physical health of patients, also affect the mental and psychological states of the patients and generate double harms of physical and mental states. Especially for patients in the childbearing age, the disease easily causes no ovulation for a long time and directly affects fertility, brings great trouble to the patients and families thereof, and becomes one of the serious problems facing the modern society.
According to the clinical symptoms and physical signs of polycystic ovarian syndrome, the polycystic ovarian syndrome belongs to the categories of ' late menstrual period ', ' amenorrhea ', ' hypomenorrhea ', ' infertility ', ' abdominal mass ', leakage ' and the like in the traditional Chinese medicine. The traditional Chinese medicine considers that the physiological function axis of a female is kidney-sex-sexual desire-Chong-conception uterus, the incidence of the polycystic ovarian syndrome is mostly caused by the disorder of the kidney-sex-sexual desire-conception uterus axis, the deficiency of the kidney is the basis of the incidence of the polycystic ovarian syndrome, and the growth and development, the exhaustion of the menstruation and the reproductive function of the female are mainly governed by the kidney qi and are closely related to sex-sexual desire. The "Fuqing Master Ladies" has cloud: "the kidney is drained through water. "woman's rule" is recorded: the irregular menstruation and the pathological changes are all in the kidney meridian. Kidney governs reproduction and mainly stores essence, which is the source of sex-stimulating essence and the root of Chong and ren meridians, the deficiency of kidney essence makes ovum difficult to develop, kidney yang deficiency can not warm spleen yang, spleen yang deficiency leads to transport and transformation disorder, which leads to qi and blood circulation obstruction and water fluid transmission disorder to form phlegm; kidney yang deficiency can not promote the biochemical growth of kidney yin, and kidney yin deficiency can not nourish uterus, resulting in menstrual water dryness. Deficiency of innate essence, deficiency of kidney qi, stagnation of qi and blood phlegm and dampness, and thoroughfare and conception vessel, blood and sea can not overflow on time, and can cause delayed menstruation, amenorrhea and infertility; stagnation of phlegm-dampness causes unsmooth qi and blood circulation, and stasis can be formed after a long time, so that the stagnation can be formed into abdominal mass, and the ovary can be changed in a polycystic manner; phlegm-dampness is accumulated in the body, and the overflowed skin can cause obesity, acne and hirsutism. The onset of polycystic ovarian syndrome is closely related to the dysfunction of the kidney, liver and spleen. Clinically, kidney deficiency is the basis, accompanied by phlegm-dampness, blood stasis, liver depression and other types, and the disease is mostly complicated by deficiency and excess. The pathogenesis is mainly kidney deficiency, accompanied by phlegm-dampness and phlegm-stasis to form deficiency-excess intermingled syndrome.
In the treatment, the western medicine mostly adopts symptomatic treatment, and medicaments such as female progestational hormone medicaments, aromatase or steroid hormone medicaments, ovulation promoting medicaments and the like are taken according to main symptoms of patients. However, long-term use of hormone drugs is prone to a series of adverse reactions, such as abnormal menstruation, ovarian hyperstimulation syndrome, obesity, and complications of diabetes, cardiovascular diseases and endometrial cancer, etc., in many patients, so that the clinical treatment scheme is limited to a great extent.
Disclosure of Invention
In view of the above-mentioned disadvantages of the prior art, the present invention aims to provide a Chinese medicinal composition, a preparation method and a use thereof, which are used for solving the problems in the prior art.
In order to achieve the above and other related objects, a first aspect of the present invention provides a Chinese medicinal composition, which comprises cinnamon, epimedium herb, prepared common monkshood daughter root, evodia rutaecarpa, glabrous greenbrier rhizome, paniculate bolbostemma rhizome, zedoary, diverse wormwood herb, safflower, salvia miltiorrhiza, cowherb seed and costustoot.
In some embodiments of the present invention, the traditional Chinese medicine composition may comprise the following components in parts by weight:
in some embodiments of the present invention, the traditional Chinese medicine composition may comprise the following components in parts by weight:
the traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of cinnamon. Cinnamon (Cortex Cinnamomi) is typically the dried bark of the plant Cinnamomum cassia (Cinnamomum cassia Presl) of the family lauraceae.
The traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of epimedium herb. Herba Epimedii (Epimedium brevicornum Maxim) is usually dry aerial part of Epimedium brevicornum Maxim of berberidaceae, Epimedium sagittatum Maxim, Epimedium pubescens Maxim, Epimedium wushanense T.S.Ying, or Epimedium koreanum Nakai.
The traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of monkshood. Radix Aconiti lateralis (Aconitum carmichaeli Debx) is usually processed product of the root of Aconitum carmichaeli Debx (Aconitum carmichaeli Debx.) belonging to family Ranunculaceae.
The traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of fructus evodiae. Fructus Evodiae (Fructus Evodiae) is generally dry near-ripe fruit of rutaecarpa (Evodia rutaecarpa (Juss.) Benth.) which is a rutaceae plant, stonewort (Evodia rutaecarpa (Juss.) Benth. var. officinalis (Dode) Huang) or Evodia rutaecarpa (Juss.) Benth. var. bodinieri (Dode) Huang).
The traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of glabrous greenbrier rhizome. Rhizoma Smilacis Glabrae (Rhizoma Smilacis Glabrae) is usually dried rhizome of Smilax glabra (Smilax Glabra Roxb.) of Liliaceae.
The traditional Chinese medicine composition comprises, by weight, 1.5-4.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, 2.3-2.5 parts, 2.5-2.7 parts, 2.7-2.9 parts, 2.9-3.1 parts, 3.1-3.3 parts, 3.3-3.5 parts, 3.5-3.7 parts, 3.7-3.9 parts, 3.9-4.1 parts, 4.1-4.3 parts, or 4.3-4.5 parts of paniculate Bolbostemma rhizome. Rhizoma Bolbostematis (Rhizoma Bolbostemtematis) is generally a dried tuber of Bolbostemma paniculatum (Maxim.) Franquet) belonging to the family Cucurbitaceae.
The traditional Chinese medicine composition comprises, by weight, 0.5-2.5 parts, 0.5-0.7 part, 0.7-0.9 part, 0.9-1.1 part, 1.1-1.3 parts, 1.3-1.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, or 2.3-2.5 parts of curcuma zedoary. Zedoary (Curcuma zedoaria (Christm.) Rosc) is usually dried rhizome of Curcuma zedoary (Curcuma phaeocaulis Val.) of zingiberaceae, Curcuma kwangsiensis (Curcuma kwangsiensis s.g. lee et c.f. liang) or Curcuma wenyujin (Curcuma wenyujin y.h.chen et c.ling).
The traditional Chinese medicine composition comprises, by weight, 0.5-2.5 parts, 0.5-0.7 part, 0.7-0.9 part, 0.9-1.1 part, 1.1-1.3 parts, 1.3-1.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, or 2.3-2.5 parts of diverse wormwood herb. Herba Artemisiae Anomalae (Herba Artemisia Anomalae) is usually aerial part of Artemisia anomala (Artemisia anomala S.Moore) belonging to Compositae.
The traditional Chinese medicine composition comprises, by weight, 0.5-2.5 parts, 0.5-0.7 part, 0.7-0.9 part, 0.9-1.1 part, 1.1-1.3 parts, 1.3-1.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, or 2.3-2.5 parts of safflower. Carthami flos (Carthamus tinctorius L) is usually dried flower of Carthamus tinctorius L of Compositae.
The traditional Chinese medicine composition comprises, by weight, 0.5-2.5 parts, 0.5-0.7 part, 0.7-0.9 part, 0.9-1.1 part, 1.1-1.3 parts, 1.3-1.5 parts, 1.5-1.7 parts, 1.7-1.9 parts, 1.9-2.1 parts, 2.1-2.3 parts, or 2.3-2.5 parts of Salvia miltiorrhiza Bunge. Salvia miltiorrhiza (Salvia milirrhiza Bunge) is typically the dried root and rhizome of Salvia miltiorrhiza (Salvia milirrhiza Bge.) belonging to the family Labiatae.
The traditional Chinese medicine composition comprises, by weight, 0.5-1.5 parts, 0.5-0.6 parts, 0.6-0.7 parts, 0.7-0.8 parts, 0.8-0.9 parts, 0.9-1.0 parts, 1.0-1.1 parts, 1.1-1.2 parts, 1.2-1.3 parts, 1.3-1.4 parts, or 1.4-1.5 parts of cowherb seeds. Semen Vaccariae (Semen Vaccariae) is usually dried mature seed of Vaccinium macrocarpon (Vaccaria segetalis (Neok.) Garcke) of Caryophyllaceae.
The traditional Chinese medicine composition comprises, by weight, 0.5-1.5 parts, 0.5-0.6 parts, 0.6-0.7 parts, 0.7-0.8 parts, 0.8-0.9 parts, 0.9-1.0 parts, 1.0-1.1 parts, 1.1-1.2 parts, 1.2-1.3 parts, 1.3-1.4 parts, or 1.4-1.5 parts of costustoot. Radix Aucklandiae (Radix Aucklandiae) is usually dried root of Aucklandia lappa Decne of Compositae.
In another aspect of the present invention, a Chinese medicinal preparation is provided, which comprises a therapeutically effective amount of the Chinese medicinal composition. The Chinese medicinal preparation can also comprise yellow wine, and each 1g of the Chinese medicinal composition can be fully mixed with 0.5-1.5 ml, 0.5-0.7 ml, 0.7-0.9 ml, 0.9-1.1 ml, 1.1-1.3 ml or 1.3-1.5 ml of yellow wine.
The traditional Chinese medicine preparation can be prepared in the form of a medicine cake, and a person skilled in the art can determine the dosage of the yellow wine according to actual needs and can select a proper mode to prepare the traditional Chinese medicine preparation through the traditional Chinese medicine preparation. For example, the preparation method of the traditional Chinese medicine preparation can comprise the following steps:
(1) mixing the traditional Chinese medicine composition according to a formula and grinding into fine powder;
(2) and (2) uniformly mixing the mixture obtained in the step (1) with yellow wine.
Preferably, in step (1), the Chinese medicinal composition may be further sieved (for example, 120 mesh sieve) after being mixed and ground into fine powder.
The invention also provides application of the traditional Chinese medicine composition or the traditional Chinese medicine preparation in preparing a medicine for treating polycystic ovarian syndrome. The polycystic ovarian syndrome can belong to a kidney deficiency and phlegm dampness type or a kidney deficiency and phlegm stasis type in the traditional Chinese medicine syndrome type. The specific diagnostic criteria and the syndrome and syndrome type criteria of the traditional Chinese medicine can be based on the Chinese and Western medicine obstetrics science [ Wukeming, Zhang Qing, Chinese and Western medicine clinical obstetrics science [ M ]. Beijing, Chinese medicine science and technology publishing agency, 2001:179] and the traditional Chinese medicine gynecology [ Mabao jade tablet, general advanced education of the traditional Chinese medicine gynecology "fifteen" planning teaching material [ M ]. Shanghai, science and technology publishing agency, 2006:66 ].
In the above use, the drug may be a moxibustion drug in general. The moxibustion medicine is generally a medicine for moxibustion treatment, and the moxibustion treatment is a treatment method for preventing and treating diseases by burning and warm-pressing moxa sticks and/or other medicines on acupuncture points on the body surface and by means of the heat of moxibustion fire and the action of the medicines and by the conduction of meridians and collaterals. The acupuncture point of the moxibustion medicine can be one or more of Guanyuan, Zhongji, ova nest and uterus. When the moxibustion medicine is directed to a pair of acupuncture points, the moxibustion medicine can be directed to one side of the acupuncture points, and can also be directed to the acupuncture points on two sides of the body, preferably to the acupuncture points on two sides simultaneously. When the moxibustion medicine is used, more strong moxibustion can be conducted at each acupoint (for example, 1-2 strong moxa sticks with the length of 1.5cm +/-0.5 cm are formed on 1-2 moxa sticks). The treatment may be performed several times per week (e.g., 2, 3, 4 or more times), and the frequency of administration may be evenly distributed, e.g., 1 treatment may be performed every 1 day. Generally, multiple sessions (e.g., 2, 3, or 4 sessions) may be treated consecutively with a menstrual cycle as the basis for determining the session, e.g., with about 1 month of the menstrual cycle or about 1 month as a session.
In the above application, the moxibustion medicine can also comprise a moxibustion box, and the Chinese medicinal composition and/or the Chinese medicinal preparation can be located in the moxibustion box. A moxibustion box is generally a box for containing a traditional Chinese medicine composition and/or a traditional Chinese medicine preparation used in a moxibustion treatment process, and the box may generally include a moxa stick fixing device (e.g., a moxa stick clip), a ventilation hole, and the like.
In the above application, the moxibustion medicine may comprise a moxa stick, and the moxa stick may be generally located on the Chinese medicinal composition and/or the Chinese medicinal preparation.
In the traditional Chinese medicine composition provided by the invention, cinnamon is pungent, sweet and hot, and can tonify fire, strengthen yang, guide fire to the origin, dispel cold, relieve pain, activate blood and dredge channels; herba Epimedii is pungent, sweet and warm, and has effects of invigorating kidney yang, strengthening tendons and bones, and dispelling pathogenic wind and dampness; the aconite root is pungent, sweet and hot, and can restore yang and restore adverse qi, supplement fire and strengthen yang, and dispel wind-cold-dampness; the evodia rutaecarpa is pungent, bitter and hot, and can dispel cold, relieve pain, check adverse rise of qi, arrest vomiting, strengthen yang and check diarrhea; rhizoma Smilacis Glabrae is sweet, bland and mild, and has effects of eliminating dampness, removing toxic substance, relieving swelling, and resolving hard mass; the rhizoma bolbostemmae is bitter and slightly cold, and can dissipate stagnation, reduce swelling and remove toxicity; the zedoary is pungent, bitter and warm, can promote qi and break blood, and can remove food retention and relieve pain; herba Artemisiae Anomalae is bitter, pungent and warm, and can break blood and dredge channels, remove food retention, stop bleeding and relieve swelling; safflower is pungent and warm, and has the effects of promoting blood circulation, dredging channels, removing blood stasis and relieving pain; the salvia miltiorrhiza is bitter and slightly cold, and can remove stasis, relieve pain, promote blood circulation, dredge channels, clear heart fire and relieve restlessness; the cowherb seed is bitter and mild, and can promote blood circulation, dredge the channels, promote lactation and reduce swelling; radix aucklandiae is pungent, bitter and warm, and has effects of activating qi, relieving pain, invigorating spleen and promoting digestion. The medicines are combined to hit the pathogenesis of kidney deficiency and phlegm dampness and kidney deficiency and phlegm stasis of polycystic ovarian syndrome. On the selected acupoints, Guanyuan and Zhongji acupoints can nourish Yuan (kidney) to strengthen the body resistance, tonify essence and blood, and regulate Chong and ren meridians; ovary or uterus point can regulate uterus, and remove blood stasis. The traditional Chinese medicine composition provided by the invention is subjected to medicine-separated moxibustion on the acupuncture points by the 12 traditional Chinese medicines, namely, the absorption of the effective components of the medicines by the skin tissues of the acupuncture points is promoted by means of the heat of moxibustion fire, so that the effects of warming yang and tonifying kidney, reducing phlegm and promoting diuresis, promoting blood circulation and removing blood stasis, and reducing swelling and dissipating stagnation are achieved, and the kidney deficiency and phlegm dampness type polycystic ovary syndrome and the kidney deficiency and phlegm stasis type polycystic ovary syndrome can be effectively treated.
Detailed Description
The embodiments of the present invention are described below with reference to specific embodiments, and other advantages and effects of the present invention will be easily understood by those skilled in the art from the disclosure of the present specification. The invention is capable of other and different embodiments and of being practiced or of being carried out in various ways, and its several details are capable of modification in various respects, all without departing from the spirit and scope of the present invention.
The compatibility of the invention accords with the principle of 'monarch, minister, assistant and guide' of the traditional Chinese medicine, the invention adopts the following traditional Chinese medicines which are compatible with each other, can play the role of the synergistic treatment of the traditional Chinese medicines, and the components of the used traditional Chinese medicine raw materials have the efficacy of mutual interweaving, mutual promotion and coordination.
The raw material medicines (or medicinal materials) adopted by the invention can be purchased from common pharmaceutical shops or Chinese medicinal material selling companies, and the specification of the raw material medicines (or medicinal materials) accords with the national pharmaceutical standard or the relevant regulations of Chinese pharmacopoeia and the like. The adopted medicinal materials are Chinese medicinal decoction pieces unless otherwise specified, and the Chinese medicinal decoction pieces can also be obtained and processed.
The term "patient" as used herein refers to humans, wild animals and livestock suffering from a disease. The wild animal is an animal which is not artificially domesticated in a natural state. Livestock are animals that are artificially raised to provide a food source, such as monkeys, apes, dogs, rats, hamsters, pigs, rabbits, horses, cows, buffalos, bulls, sheep, and goats, and the like. The "patient" to be administered the diagnosis is preferably a mammal, especially a human.
In the embodiment, all the traditional Chinese medicine materials are common commercial products, and the specification of the traditional Chinese medicine materials accords with the corresponding national medicine standard or the relevant regulations of Chinese pharmacopoeia and the like. All the traditional Chinese medicine materials are traditional Chinese medicine decoction pieces, and the production places are as follows: the producing areas of the components are respectively as follows: cinnamon (Guangdong), epimedium (Shaanxi), monkshood (Sichuan), evodia rutaecarpa (Guizhou), glabrous greenbrier rhizome (Guangdong), rhizoma bolbostemmae (Hebei), zedoary (Guangxi), diverse wormwood herb (Henan), safflower (Henan), salvia miltiorrhiza (Sichuan), cowherb seed (Hebei) and costus root (Yunnan).
The moxa stick used in the examples is prepared from Huatuo refined moxibustion pure moxa stick (produced by Suzhou) with reliable quality.
Example 1
Weighing 15g of cinnamon (Guangdong), 15g of epimedium (Shaanxi), 15g of monkshood (Sichuan), 15g of evodia rutaecarpa (Guizhou), 15g of glabrous greenbrier rhizome (Guangdong), 15g of rhizoma bolbostemmae (Hebei), 9g of zedoary (Guangxi), 9g of diverse wormwood herb (Henan), 9g of safflower (Henan), 9g of salvia miltiorrhiza (Sichuan), 5g of cowherb seed (Hebei) and 5g of costus root (Yunnan), uniformly mixing, crushing into fine powder, sieving by a 120-mesh sieve, weighing 2.5g of +/-0.5 g of fine powder, mixing with 2.5ml of +/-0.5 ml of yellow wine, stirring into thick paste, pressing into medicine cakes with the diameter of 2.5cm and the thickness of 0.8cm by using a mould, and storing at the temperature of 4 ℃. When the treatment is carried out, 1.5cm +/-0.5 cm moxa stick segment (namely 1 Zhuang) is placed on the medicine cake and subjected to medicine-separated moxibustion treatment at the acupuncture point. Point selection, Guanyuan, Zhongji, Yun-ao or Yun-ao (both sides). Each acupoint is 2 strong moxibustion every time, 3 times per week, 1 month menstruation period or 1 month as a treatment course, and 3 treatment courses are continuously performed.
Example 2
1. And (3) inclusion standard: clinically, 60 patients with kidney deficiency and phlegm dampness type and kidney deficiency and phlegm stasis type polycystic ovarian syndrome are 14-49 years old and female.
And (3) Western diagnosis: according to the Lutepan standard issued by the European research center for human reproduction and embryology and the American society for reproductive medicine in 2003 [ Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus workshops group. Recessed 2003 coherent on diagnostic criteria criterion and long-term health related to polycystic ovarian syndrome [ J ]. FertlSteril Steril,2004,81(1):19-25] and the Chinese medical guideline for polycystic ovarian syndrome issued by the Chinese medical society for gynaecology and obstetrics division and guideline expert group [ the Chinese medical society for gynaecology and obstetrics division and guideline expert group. the Chinese medical guideline for polycystic ovarian syndrome [ J ]. Chinese J.gynaecology and obstetrics, 2018,53(1):2-6 ]. PCOS can be diagnosed whenever any two of the following criteria are met: (1) infrequent or no ovulation; (2) hyperandrogenism or clinical manifestations of hyperandrogenism (e.g., hirsutism, acne, etc.); (3) ultrasonic examination shows that the bilateral ovaries have more than or equal to 12 small follicles with the diameter of 2-9mm, and/or the volume of the ovaries is more than or equal to 10ml (the volume of the ovaries is calculated by 0.5 multiplied by the long diameter multiplied by the transverse diameter multiplied by the anteroposterior diameter). At least 2 of the indexes meet, and hyperandrogenism or hyperandrogenism symptoms caused by other causes such as cushing's syndrome, atypical congenital adrenal cortical hyperplasia, ovarian or adrenal androgen-secreting tumors, and the like are excluded; meanwhile, ovulation disorder caused by functional hypothalamic amenorrhea, thyroid disease, high PRL blood disease, premature ovarian insufficiency and other causes is eliminated.
2. Grouping: the 60 patients were randomly divided into 2 groups, 30 in the observation group and 30 in the control group.
3. The treatment method comprises the following steps: acupuncture points of Guanyuan, Zhongji, ovary or uterus (on both sides) are selected for moxibustion treatment by drug-separated moxibustion.
Each observation group was 2 strong moxibustion; the control group was treated with pseudo-medial moxibustion, which was performed in the same manner as the observation group, but warm feeling was felt only when there was no drug penetration in the acupuncture point region by placing a heat-insulating paper sheet between the moxa cone and the cake.
The two groups are treated 3 times per week, with 1 month cycle or 1 month as a treatment course, and 3 treatment courses are continued.
After 3 treatment sessions, the two groups of treatment results were as follows:
in tables 1 to 6, healing occurred: the menstrual cycle is basically normal, the color, quality and quantity of the menstrual blood are normal, the development of follicles under B-ultrasound is normal or the Basal Body Temperature (BBT) is biphasic, the indexes of related hormones are normal, and the Chinese medicine symptom curative effect index is more than or equal to 90 percent; the method has the following advantages: the menstrual cycle and the color, quality and quantity of the menstruation are improved, the development of follicles under B-ultrasonography is improved (the number of follicles in each side of ovary is less than 10 or the ovary volume is reduced compared with that before treatment) or BBT has two phases, the related hormone indexes are improved, and the Chinese medicine symptom curative effect index is more than or equal to 33.3 percent; and (4) invalidation: before and after treatment, symptoms, related hormone indexes and B-mode ultrasonography or BBT are not changed, and the Chinese medicine symptom curative effect index is less than 33.3 percent. Calculated by a nimodipine method, the curative effect index (n) is (integration before treatment-integration after treatment)/integration before treatment x 100%. And (3) healing: the Chinese medicine symptom curative effect index is more than or equal to 90 percent; the method has the following advantages: the Chinese medicine symptom curative effect index is more than or equal to 33.3 percent; and (4) invalidation: the Chinese medicine has curative index of less than 33.3%. The therapeutic standard is formulated according to the relevant contents in the guiding principle of clinical research of new traditional Chinese medicine and the diagnosis and treatment guide of common gynecological diseases issued by the national ministry of health in 2002 [ Zheng Xiao Dou, guiding principle (trial) [ M ] of clinical research of new traditional Chinese medicine and Beijing, China pharmaceutical science and technology publishing agency, 2002,239 and 242; the society of Chinese medicine and pharmacy, diagnosis and treatment guide of gynecological common diseases of traditional Chinese medicine [ M ]. Beijing, Chinese medicine publishing society, 2012.
TABLE 1 comparison of the post-treatment efficacy of the two groups of patients
Note: compared with the control group, the compound of the formula,##p is less than 0.01, and the clinical curative effect of the observation group isThe upper is obviously better than the control group.
TABLE 2 post-treatment BBT comparison of two groups of patients
Note: compared with the control group, the compound of the formula,##p is less than 0.01, and the observed group is obviously superior to the control group in improving BBT.
TABLE 3 comparison of the scores of the traditional Chinese medicine syndrome after the treatment of two groups of patients
Note: compared with the control group, the compound of the formula,##p is less than 0.01, and the observation group is obviously superior to the control group in the score of improving the traditional Chinese medicine syndrome curative effect.
TABLE 4 comparison of testosterone (T) levels after treatment in two groups of patients
Note: compared with the control group, the compound of the formula,#p is less than 0.05, and the observed group is superior to the control group in reducing the T level.
TABLE 5 comparison of Luteinizing Hormone (LH) levels after treatment in two groups of patients
Note: compared with the control group, the compound of the formula,#p is less than 0.05, and the observed group is superior to the control group in reducing LH level.
TABLE 6 comparison of anti-Mullerian hormone (AMH) levels after treatment in two groups of patients
Note: compared with the control group, the compound of the formula,#p is less than 0.05, and the observed group is superior to the control group in reducing AMH level.
In conclusion, the present invention effectively overcomes various disadvantages of the prior art and has high industrial utilization value. The foregoing embodiments are merely illustrative of the principles and utilities of the present invention and are not intended to limit the invention. Any person skilled in the art can modify or change the above-mentioned embodiments without departing from the spirit and scope of the present invention. Accordingly, it is intended that all equivalent modifications or changes which can be made by those skilled in the art without departing from the spirit and technical spirit of the present invention be covered by the claims of the present invention.
Claims (10)
1. A Chinese medicinal composition comprises cortex Cinnamomi, herba Epimedii, radix Aconiti lateralis Preparata, fructus evodiae, rhizoma Smilacis Glabrae, rhizoma Bolbostematis, Curcumae rhizoma, herba Artemisiae Anomalae, Carthami flos, Saviae Miltiorrhizae radix, semen Vaccariae and radix aucklandiae.
2. The traditional Chinese medicine composition of claim 1, which comprises the following components in parts by weight:
3. the traditional Chinese medicine composition of claim 2, which comprises the following components in parts by weight:
4. a Chinese medicinal preparation comprising a therapeutically effective amount of the Chinese medicinal composition of any one of claims 1-3.
5. The Chinese medicinal preparation of claim 4, wherein the Chinese medicinal preparation further comprises yellow wine.
6. The traditional Chinese medicine preparation of claim 5, wherein in the traditional Chinese medicine preparation, each 1g of the traditional Chinese medicine composition is mixed with 0.5-1.5 ml of yellow wine;
and/or the yellow wine is selected from Shaoxing yellow wine.
7. Use of the Chinese medicinal composition according to any one of claims 1 to 3 and the Chinese medicinal preparation according to any one of claims 4 to 6 for preparing a medicament for treating polycystic ovary syndrome.
8. The use of claim 7, wherein the medicament is a moxibustion medicament;
and/or the polycystic ovary syndrome is a kidney deficiency and phlegm dampness type or a kidney deficiency and phlegm stasis type.
9. The use of claim 7, wherein the moxibustion is directed at acupuncture points selected from the group consisting of: one or more of Guanyuan, Zhongji, Luoyao and Yuxue.
10. The use of claim 7, wherein the moxibustion drug comprises a moxa stick, the moxa stick being located on the traditional Chinese medicine composition and/or the traditional Chinese medicine preparation.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110619720.6A CN113197991B (en) | 2021-06-03 | 2021-06-03 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110619720.6A CN113197991B (en) | 2021-06-03 | 2021-06-03 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113197991A true CN113197991A (en) | 2021-08-03 |
| CN113197991B CN113197991B (en) | 2022-06-07 |
Family
ID=77024107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110619720.6A Active CN113197991B (en) | 2021-06-03 | 2021-06-03 | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113197991B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117323371A (en) * | 2023-10-30 | 2024-01-02 | 四川大学华西第二医院 | Traditional Chinese medicine composition for treating obesity type polycystic ovary syndrome and preparation method thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832835A (en) * | 2016-06-13 | 2016-08-10 | 刘晓安 | Traditional Chinese medicine fumigating composition for treating cervical spondylosis and use method thereof |
-
2021
- 2021-06-03 CN CN202110619720.6A patent/CN113197991B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105832835A (en) * | 2016-06-13 | 2016-08-10 | 刘晓安 | Traditional Chinese medicine fumigating composition for treating cervical spondylosis and use method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 施茵等: "针灸治疗肥胖型多囊卵巢综合征的临床疗效观察", 《中华中医药学刊》 * |
| 章巧萍: "浅谈补肾活血法治疗多囊卵巢综合征", 《中国中医药信息杂志》 * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN117323371A (en) * | 2023-10-30 | 2024-01-02 | 四川大学华西第二医院 | Traditional Chinese medicine composition for treating obesity type polycystic ovary syndrome and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113197991B (en) | 2022-06-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101502634B (en) | Chinese medicinal composition for treating uterine blood flow and preparation method thereof | |
| CN101496862B (en) | Chinese medicinal composition for treating infertility and preparation method thereof | |
| CN100402081C (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN102526417B (en) | Traditional Chinese medicine for treating sterility caused by palace cold | |
| CN104258066A (en) | Traditional Chinese medicine preparation for treating kidney-yin deficiency-type dysfunctional uterine bleeding, and preparation method thereof | |
| CN104922613A (en) | Medicine composite for treating sterility and preparation method thereof | |
| CN113197991B (en) | Traditional Chinese medicine composition for treating polycystic ovarian syndrome and preparation method and application thereof | |
| CN109528980A (en) | A kind of Chinese medicine composition and its pharmacy application for treating Ovary reserve decline disease | |
| CN102441111B (en) | Chinese patent medicine used for treating infertility, and preparation method thereof | |
| CN104524478A (en) | External traditional Chinese medicine preparation for treating amenorrhea and preparation method thereof | |
| CN105395842A (en) | Traditional Chinese medicine composition for treating diabetes and oral preparation and preparation method thereof | |
| CN103520354B (en) | Traditional Chinese medicine for treatment of blood-insufficiency type mammary gland hyperplasia and preparation method thereof | |
| CN108619471B (en) | Danhuang stasis removing capsule and preparation process thereof | |
| CN102641373A (en) | Traditional Chinese medicine combination used for treating psoriasis | |
| CN105343847A (en) | Traditional Chinese medicine composition for treating eczema containing folium artemisiae argyi and preparing method thereof | |
| CN111658748A (en) | Composition for treating dysmenorrhea, oral preparation and application | |
| CN104257813B (en) | A kind of Chinese medicine composition of QI and blood regulating and preparation method thereof | |
| CN110876781B (en) | Traditional Chinese medicine composition for treating kidney-yin deficiency type intermenstrual bleeding and night sweat and application thereof | |
| CN102526590B (en) | Chinese medicament for improving IVF-ET post-implantation dysfunction | |
| CN105412768A (en) | Medicine composition for treating infertility and preparation method thereof | |
| CN106177451A (en) | The Chinese medicine suppository preparation method for the treatment of women's ovary senilism and suppository thereof | |
| CN106994158A (en) | It is a kind of to treat Chinese medicine composition of ovarian cyst and its production and use | |
| CN105169342A (en) | Traditional Chinese medicine composition for treating eczema and preparation method thereof | |
| CN104606537A (en) | Qi-reinforcing and blood-nourishing medicated diet for improving chemotherapy-induced myocardial ischemic injury and preparation method | |
| CN113318167A (en) | Traditional Chinese medicine composition for treating rheumatoid arthritis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |